Hypolipidaemic properties of a new tetralin derivative (CIBA 13,437-Su).
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D000963:Antimetabolites / Q000494:pharmacology*; D002784:Cholesterol / Q000032:analysis; D005989:Glycerides / Q000097:blood; D000960:Hypolipidemic Agents / Q000494:pharmacology; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D008112:Liver Glycogen / Q000032:analysis; D008297:Male; D009281:Naphthalenes / Q000494:pharmacology*; D009929:Organ Size; D010743:Phospholipids / Q000032:analysis; D011422:Propionates; D011506:Proteins / Q000032:analysis; D051381:Rats
D000924:Anticholesteremic Agents; D000963:Antimetabolites; D005989:Glycerides; D000960:Hypolipidemic Agents; D008055:Lipids; D008112:Liver Glycogen; D009281:Naphthalenes; D010743:Phospholipids; D011422:Propionates; D011506:Proteins; D002784:Cholesterol